Humana Inc (HUM)

Nov 11, 2026

Humana Inc. (NYSE:HUM) has an average "Moderate Buy" rating from thirty-two research firms, with an average one-year price target of $469.57. Following strong third-quarter earnings and a raised 2026 adjusted EPS outlook, several brokerages increased their price targets. The company also recently declared a quarterly dividend of $0.8850.

Nov 10, 2026

Securitize Holdings (NYSE: SECZ) shares surged after the company reported third-quarter revenue of $18.61 million, beating analyst expectations. Despite a wider-than-expected per-share loss, much of it was attributed to non-cash expenses. The company also announced a $50 million share repurchase plan and the acquisition of River Credit Labs (River One), alongside reaching a record $5 billion in average tokenized assets.

Nov 10, 2026

The nation's largest health insurers reported a record $449 billion in revenue and $9.2 billion in profits in Q3, exceeding analyst expectations. This growth was driven by strategies focused on charging more, covering less, and shifting financial risk, rather than expanding access or improving services. While investors celebrate, these practices raise concerns about healthcare affordability and accessibility for Americans, as evidenced by declining enrollment in fully insured plans and rising costs for consumers.

Nov 10, 2026

UnitedHealth Group (NYSE:UNH) reported strong Q3 results on October 13, surpassing analyst forecasts for adjusted earnings per share and improving its medical care ratio. While total membership was slightly below expectations, reflecting a strategy to prioritize profitable business, the company raised its full-year earnings outlook. The positive report offers insights into the broader healthcare sector, though regulatory scrutiny and ongoing medical cost trends remain factors to monitor.

Nov 9, 2026

Humana Inc. reported better-than-expected third-quarter results with a narrower loss and raised its fiscal 2026 adjusted earnings per share guidance. Following the announcement, several analysts from Cantor Fitzgerald, Barclays, Guggenheim, and Piper Sandler maintained their "Overweight" or "Buy" ratings and increased their price targets for Humana shares. The company's President and CEO, Jim Rechtin, expressed satisfaction with the positive results and improved financial performance.

Nov 9, 2026

Brown & Brown's 2027 Employer Health and Benefits Strategy Survey indicates that rising healthcare costs are compelling employers to prioritize organizational cost control over employee benefits affordability. While employers are implementing aggressive cost-containment measures like benefits audits and PBM evaluations, they also maintain a commitment to employee well-being and mental health support. The survey also highlights the challenge of balancing GLP-1 medication coverage with budget constraints.

Nov 8, 2026

Healthcare Services Group (NASDAQ:HCSG) has received a "Moderate Buy" rating from Wall Street analysts, with an average 12-month price target of $26.67. The company's recent quarterly earnings of $0.36 per share surpassed estimates, though revenue was slightly below expectations and EPS decreased year-over-year. Insider selling by an executive was also noted.

Nov 7, 2026

Sanders Capital LLC reduced its stake in HCA Healthcare by 0.4% in the third quarter, selling 36,505 shares but still holding 8.79 million shares valued at approximately $3.75 billion. HCA Healthcare reported strong quarterly earnings of $7.22 per share, surpassing analyst estimates, with revenue rising 3.6% year-over-year to $19.85 billion. Despite some insider selling totaling $16.5 million, analysts maintain a "Moderate Buy" rating with a consensus price target of $480.13.

Nov 6, 2026

Humana Inc. (NYSE: HUM) shares rose about 4% after the health insurer reported a narrower-than-expected third-quarter loss and beat revenue estimates. The company raised its fiscal 2026 adjusted earnings per share guidance to at least $9.50 and its GAAP EPS guidance to at least $15.09. Humana also saw a surge in Medicare Advantage membership and improved its insurance segment benefit ratio.

Nov 6, 2026

Humana reported a third-quarter net income of $162 million, a decrease from the previous year, primarily due to rising care costs for new Medicare Advantage enrollees. The company's insurance benefit ratio increased to 93.7%, largely attributed to over 1 million new Medicare Advantage members who typically have a higher benefit ratio. Despite the dip in profits, Humana saw revenue jump to $41.2 billion and raised its full-year 2026 adjusted earnings per share guidance to at least $9.50.

Nov 6, 2026

Humana raised its full-year earnings outlook after reporting a significant jump in third-quarter revenue, which rose 26% to $41.16 billion, exceeding Wall Street estimates. The health insurer now anticipates 2026 earnings of at least $15.09 a share, an increase from its previous forecast. Adjusted full-year guidance was also lifted to at least $9.50 a share.

Nov 5, 2026

Conduent reported Q3 2026 revenue of $534 million, a sequential increase from Q2, and an adjusted EBITDA of $36 million with a 6.7% margin. The company is focused on its Ascend 2026–2028 plan, prioritizing pipeline conversion, portfolio optimization, cost reduction, and AI integration. With divestitures expected to yield $234 million and a refinanced credit facility, Conduent aims for sustainable, profitable growth, positive free cash flow, and improved margins over the next three years.

Nov 5, 2026

Shares of healthcare services company Agilon Health (AGL) surged 17.5% after reporting strong third-quarter 2026 earnings, swinging from a net loss to a net profit of $35 million and achieving significant revenue growth. The company also saw a recovery in adjusted EBITDA and a decline in its medical services expense ratio, indicating improved operating efficiency. Despite high volatility and a substantial year-to-date gain, the stock remains below its 52-week high.

Nov 5, 2026

The Cigna Group reported a third-quarter net income of $1.4 billion, a decrease from $1.9 billion in the prior year, despite a six percent increase in total revenues to $73.7 billion. This growth was driven by its Evernorth Health Services and Cigna Healthcare segments, alongside better management of medical costs. The company subsequently raised its 2026 adjusted income outlook to at least $30.60 per share, with its medical cost ratio slightly increasing to 85 percent.

Nov 4, 2026

Humana (NYSE: HUM) is set to report its Q3 results, with analysts expecting a 25.2% year-on-year revenue growth. The health insurance company previously beat revenue and EPS estimates last quarter, adding 200,800 customers. Competitors Elevance Health and CVS Health have also reported Q3 results, showing positive sentiment in the health insurance sector.

Nov 4, 2026

CVS Health announced plans to split into two separate public companies by the first half of 2028, reversing its $78 billion acquisition of Aetna in 2018. The move will separate CVS's 9,000 retail pharmacies from its insurance business and pharmacy benefit manager, Caremark. Following the announcement, CVS shares closed over 12% lower, despite the CEO stating the decision comes "out of a position of strength" due to business recovery.

Nov 4, 2026

CVS Health announced its decision to split its pharmacy chain and insurance businesses into two independent companies, reversing its previous integrated healthcare strategy. The separation is expected to be completed by the first half of 2028. David Joyner will lead the healthcare insurance company, and Prem Shah will be CEO of the CVS Pharmacy unit.

Nov 3, 2026

CVS Health is reportedly considering splitting its retail pharmacy chain from its insurance business, according to the Financial Times. This potential move would undo part of the healthcare conglomerate built through various acquisitions, including the 2018 purchase of Aetna. Discussions are still in the early stages, and no final decision has been made.

Nov 3, 2026

Sumitomo Mitsui Trust Group Inc. reduced its stake in Humana Inc. by 3.1% in the third quarter, selling 7,800 shares but still retaining 247,637 shares valued at $94.5 million. Despite this sale, institutional investors hold a significant 92.38% of Humana's stock, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $453.30. Humana also declared a quarterly dividend of $0.885 per share, resulting in an annualized payout of $3.54 and a 0.9% yield.

Nov 3, 2026

Cigna Group (CI) is preparing to report its third-quarter 2026 results, with analysts anticipating a slight decrease in earnings per share but an increase in revenues. While pharmacy and Cigna Healthcare revenues are expected to grow, the Evernorth Health Services segment's pre-tax adjusted income is projected to decline. The article also highlights other medical stocks, Phibro Animal Health Corporation, ProMIS Neurosciences, Inc., and Humana Inc., that show potential for an earnings beat.

Nov 3, 2026

Healthcare investors are betting on a "Blue Wave" election outcome to benefit hospital operators, anticipating a reversal of Trump's Medicaid cuts. However, the article cautions against this assumption, reminding investors of past difficulties in rolling back healthcare agendas when an opposition party gained control. The piece suggests that such a reversal might be harder to achieve than markets currently anticipate.

Nov 2, 2026

DataMEDS AI (NASDAQ: MEDS) announced that its subsidiary, Corexa Health, has secured an agreement to commercially supply bulk drug substances and active pharmaceutical ingredients for six peptides, with Corexa Pharmacy beginning dispensation in November 2026. This move aligns with updated U.S. Department of Health and Human Services’ policy and aims to offer a pharmacy-compounded alternative to unregulated peptide products. The company will also use its mobile app to collect safety data and support Corexa Health's logistics business.

Nov 2, 2026

Virtue Capital Management LLC recently acquired 3,613 shares of Humana Inc. (NYSE:HUM) stock, valued at approximately $1.38 million. This purchase is part of broader institutional investment, with hedge funds and other institutional investors collectively owning 92.38% of Humana's outstanding stock. Analysts maintain a "Moderate Buy" consensus rating for Humana, with an average price target of $453.30, and the company has declared a quarterly dividend of $0.885 per share.

Oct 31, 2026

Zacks Research has upgraded Healthcare Services Group (NASDAQ:HCSG) from a "hold" to a "strong-buy" rating. This upgrade comes as HCSG shares opened up 2.6% at $24.68, nearing their 12-month high, and after the company reported quarterly EPS of $0.36, surpassing the consensus estimate. Institutional investors hold a significant portion of the stock, while some executives have recently sold shares.

Oct 30, 2026

Humana Inc. (NYSE:HUM) has declared a quarterly dividend of $0.885 per share, totaling $3.54 annually with a 0.9% yield. Shareholders of record on December 24, 2026, will receive the payment on January 29, 2027. The dividend is well-covered, supported by the company's recent earnings beat where it reported $7.61 EPS, exceeding the $7.27 consensus, and a 26.2% year-over-year revenue increase to $40.89 billion.

Oct 30, 2026

Humana Inc. (HUM) is currently testing support levels, with weak near-term sentiment potentially challenging long-term strength. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each incorporating risk management parameters. The analysis highlights an exceptional 59.8:1 risk-reward setup, targeting a 17.3% gain against 0.3% risk.